Evaluation	O
of	O
the	O
Prostate	B:C4284879
Imaging	I:C4284879
Reporting	I:C4284879
and	I:C4284879
Data	I:C4284879
System	I:C4284879
for	O
Magnetic	O
Resonance	I:C0024485
Imaging	I:C0024485
Diagnosis	O
of	O
Prostate	O
Cancer	I:C0376358
in	O
Patients	O
with	O
Prostate	O
-	I:C0138741
specific	I:C0138741
Antigen	I:C0138741
<	O
20	O
ng/	O
ml	O
.	O

Evaluation	O
of	O
the	O
Prostate	O
Imaging	I:C4284879
Reporting	I:C4284879
and	I:C4284879
Data	I:C4284879
System	I:C4284879
for	O
Magnetic	B:C0024485
Resonance	I:C0024485
Imaging	I:C0024485
Diagnosis	O
of	O
Prostate	O
Cancer	I:C0376358
in	O
Patients	O
with	O
Prostate	O
-	I:C0138741
specific	I:C0138741
Antigen	I:C0138741
<	O
20	O
ng/	O
ml	O
.	O

Evaluation	O
of	O
the	O
Prostate	O
Imaging	I:C4284879
Reporting	I:C4284879
and	I:C4284879
Data	I:C4284879
System	I:C4284879
for	O
Magnetic	O
Resonance	I:C0024485
Imaging	I:C0024485
Diagnosis	B:C1704656
of	O
Prostate	O
Cancer	I:C0376358
in	O
Patients	O
with	O
Prostate	O
-	I:C0138741
specific	I:C0138741
Antigen	I:C0138741
<	O
20	O
ng/	O
ml	O
.	O

Evaluation	O
of	O
the	O
Prostate	O
Imaging	I:C4284879
Reporting	I:C4284879
and	I:C4284879
Data	I:C4284879
System	I:C4284879
for	O
Magnetic	O
Resonance	I:C0024485
Imaging	I:C0024485
Diagnosis	O
of	O
Prostate	B:C0376358
Cancer	I:C0376358
in	O
Patients	O
with	O
Prostate	O
-	I:C0138741
specific	I:C0138741
Antigen	I:C0138741
<	O
20	O
ng/	O
ml	O
.	O

Evaluation	O
of	O
the	O
Prostate	O
Imaging	I:C4284879
Reporting	I:C4284879
and	I:C4284879
Data	I:C4284879
System	I:C4284879
for	O
Magnetic	O
Resonance	I:C0024485
Imaging	I:C0024485
Diagnosis	O
of	O
Prostate	O
Cancer	I:C0376358
in	O
Patients	O
with	O
Prostate	B:C0138741
-	I:C0138741
specific	I:C0138741
Antigen	I:C0138741
<	O
20	O
ng/	O
ml	O
.	O

The	O
European	B:C1708333
Society	I:C1708333
of	I:C1708333
Urogenital	I:C1708333
Radiology	I:C1708333
has	O
built	O
the	O
Prostate	O
Imaging	I:C4284879
Reporting	I:C4284879
and	I:C4284879
Data	I:C4284879
System	I:C4284879
(	O
Prostate	O
Imaging	I:C4284879
Reporting	I:C4284879
and	I:C4284879
Data	I:C4284879
System	I:C4284879
)	O
for	O
standardizing	O
the	O
diagnosis	O
of	O
prostate	O
cancer	I:C0376358
(	O
prostate	O
cancer	I:C0376358
)	O
.	O

The	O
European	O
Society	I:C1708333
of	I:C1708333
Urogenital	I:C1708333
Radiology	I:C1708333
has	O
built	O
the	O
Prostate	B:C4284879
Imaging	I:C4284879
Reporting	I:C4284879
and	I:C4284879
Data	I:C4284879
System	I:C4284879
(	O
Prostate	O
Imaging	I:C4284879
Reporting	I:C4284879
and	I:C4284879
Data	I:C4284879
System	I:C4284879
)	O
for	O
standardizing	O
the	O
diagnosis	O
of	O
prostate	O
cancer	I:C0376358
(	O
prostate	O
cancer	I:C0376358
)	O
.	O

The	O
European	O
Society	I:C1708333
of	I:C1708333
Urogenital	I:C1708333
Radiology	I:C1708333
has	O
built	O
the	O
Prostate	O
Imaging	I:C4284879
Reporting	I:C4284879
and	I:C4284879
Data	I:C4284879
System	I:C4284879
(	O
Prostate	B:C4284879
Imaging	I:C4284879
Reporting	I:C4284879
and	I:C4284879
Data	I:C4284879
System	I:C4284879
)	O
for	O
standardizing	O
the	O
diagnosis	O
of	O
prostate	O
cancer	I:C0376358
(	O
prostate	O
cancer	I:C0376358
)	O
.	O

The	O
European	O
Society	I:C1708333
of	I:C1708333
Urogenital	I:C1708333
Radiology	I:C1708333
has	O
built	O
the	O
Prostate	O
Imaging	I:C4284879
Reporting	I:C4284879
and	I:C4284879
Data	I:C4284879
System	I:C4284879
(	O
Prostate	O
Imaging	I:C4284879
Reporting	I:C4284879
and	I:C4284879
Data	I:C4284879
System	I:C4284879
)	O
for	O
standardizing	O
the	O
diagnosis	B:C1704656
of	O
prostate	O
cancer	I:C0376358
(	O
prostate	O
cancer	I:C0376358
)	O
.	O

The	O
European	O
Society	I:C1708333
of	I:C1708333
Urogenital	I:C1708333
Radiology	I:C1708333
has	O
built	O
the	O
Prostate	O
Imaging	I:C4284879
Reporting	I:C4284879
and	I:C4284879
Data	I:C4284879
System	I:C4284879
(	O
Prostate	O
Imaging	I:C4284879
Reporting	I:C4284879
and	I:C4284879
Data	I:C4284879
System	I:C4284879
)	O
for	O
standardizing	O
the	O
diagnosis	O
of	O
prostate	B:C0376358
cancer	I:C0376358
(	O
prostate	O
cancer	I:C0376358
)	O
.	O

The	O
European	O
Society	I:C1708333
of	I:C1708333
Urogenital	I:C1708333
Radiology	I:C1708333
has	O
built	O
the	O
Prostate	O
Imaging	I:C4284879
Reporting	I:C4284879
and	I:C4284879
Data	I:C4284879
System	I:C4284879
(	O
Prostate	O
Imaging	I:C4284879
Reporting	I:C4284879
and	I:C4284879
Data	I:C4284879
System	I:C4284879
)	O
for	O
standardizing	O
the	O
diagnosis	O
of	O
prostate	O
cancer	I:C0376358
(	O
prostate	B:C0376358
cancer	I:C0376358
)	O
.	O

This	O
study	B:C2603343
evaluated	O
the	O
Prostate	O
Imaging	I:C4284879
Reporting	I:C4284879
and	I:C4284879
Data	I:C4284879
System	I:C4284879
diagnosis	O
method	I:C0430022
in	O
patients	O
with	O
prostate	O
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
(	O
prostate	O
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
)	O
<	O
20	O
ng	O
/	O
ml	O
.	O

This	O
study	O
evaluated	O
the	O
Prostate	B:C4284879
Imaging	I:C4284879
Reporting	I:C4284879
and	I:C4284879
Data	I:C4284879
System	I:C4284879
diagnosis	O
method	I:C0430022
in	O
patients	O
with	O
prostate	O
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
(	O
prostate	O
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
)	O
<	O
20	O
ng	O
/	O
ml	O
.	O

This	O
study	O
evaluated	O
the	O
Prostate	O
Imaging	I:C4284879
Reporting	I:C4284879
and	I:C4284879
Data	I:C4284879
System	I:C4284879
diagnosis	B:C0430022
method	I:C0430022
in	O
patients	O
with	O
prostate	O
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
(	O
prostate	O
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
)	O
<	O
20	O
ng	O
/	O
ml	O
.	O

This	O
study	O
evaluated	O
the	O
Prostate	O
Imaging	I:C4284879
Reporting	I:C4284879
and	I:C4284879
Data	I:C4284879
System	I:C4284879
diagnosis	O
method	I:C0430022
in	O
patients	O
with	O
prostate	B:C0138741
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
(	O
prostate	O
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
)	O
<	O
20	O
ng	O
/	O
ml	O
.	O

This	O
study	O
evaluated	O
the	O
Prostate	O
Imaging	I:C4284879
Reporting	I:C4284879
and	I:C4284879
Data	I:C4284879
System	I:C4284879
diagnosis	O
method	I:C0430022
in	O
patients	O
with	O
prostate	O
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
(	O
prostate	B:C0138741
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
)	O
<	O
20	O
ng	O
/	O
ml	O
.	O

A	O
total	O
of	O
133	O
patients	O
with	O
prostate	B:C0138741
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
<	O
20	O
ng	O
/	O
ml	O
were	O
prospectively	O
recruited	O
.	O

T2	B:C0011923
-	I:C0011923
weighted	I:C0011923
(	O
T2	O
-	I:C0011923
weighted	I:C0011923
)	O
and	O
diffusion	O
-	I:C0598801
weighted	I:C0598801
(	I:C0598801
DWI	I:C0598801
)	I:C0598801
magnetic	I:C0598801
resonance	I:C0598801
images	I:C0598801
of	O
the	O
prostate	O
were	O
acquired	O
before	O
a	O
12	O
-	I:C0401641
core	I:C0401641
transrectal	I:C0401641
prostate	I:C0401641
biopsy	I:C0401641
.	O

T2	O
-	I:C0011923
weighted	I:C0011923
(	O
T2	B:C0011923
-	I:C0011923
weighted	I:C0011923
)	O
and	O
diffusion	O
-	I:C0598801
weighted	I:C0598801
(	I:C0598801
DWI	I:C0598801
)	I:C0598801
magnetic	I:C0598801
resonance	I:C0598801
images	I:C0598801
of	O
the	O
prostate	O
were	O
acquired	O
before	O
a	O
12	O
-	I:C0401641
core	I:C0401641
transrectal	I:C0401641
prostate	I:C0401641
biopsy	I:C0401641
.	O

T2	O
-	I:C0011923
weighted	I:C0011923
(	O
T2	O
-	I:C0011923
weighted	I:C0011923
)	O
and	O
diffusion	B:C0598801
-	I:C0598801
weighted	I:C0598801
(	I:C0598801
DWI	I:C0598801
)	I:C0598801
magnetic	I:C0598801
resonance	I:C0598801
images	I:C0598801
of	O
the	O
prostate	O
were	O
acquired	O
before	O
a	O
12	O
-	I:C0401641
core	I:C0401641
transrectal	I:C0401641
prostate	I:C0401641
biopsy	I:C0401641
.	O

T2	O
-	I:C0011923
weighted	I:C0011923
(	O
T2	O
-	I:C0011923
weighted	I:C0011923
)	O
and	O
diffusion	O
-	I:C0598801
weighted	I:C0598801
(	I:C0598801
DWI	I:C0598801
)	I:C0598801
magnetic	I:C0598801
resonance	I:C0598801
images	I:C0598801
of	O
the	O
prostate	B:C0033572
were	O
acquired	O
before	O
a	O
12	O
-	I:C0401641
core	I:C0401641
transrectal	I:C0401641
prostate	I:C0401641
biopsy	I:C0401641
.	O

T2	O
-	I:C0011923
weighted	I:C0011923
(	O
T2	O
-	I:C0011923
weighted	I:C0011923
)	O
and	O
diffusion	O
-	I:C0598801
weighted	I:C0598801
(	I:C0598801
DWI	I:C0598801
)	I:C0598801
magnetic	I:C0598801
resonance	I:C0598801
images	I:C0598801
of	O
the	O
prostate	O
were	O
acquired	O
before	O
a	O
12	B:C0401641
-	I:C0401641
core	I:C0401641
transrectal	I:C0401641
prostate	I:C0401641
biopsy	I:C0401641
.	O

Each	O
patient	O
's	O
peripheral	B:C0458696
zone	I:C0458696
was	O
divided	O
into	O
six	O
regions	O
on	O
the	O
images	O
;	O
each	O
region	O
corresponded	O
to	O
two	O
of	O
the	O
12	O
biopsy	O
cores	O
.	O

Each	O
patient	O
's	O
peripheral	O
zone	I:C0458696
was	O
divided	O
into	O
six	O
regions	O
on	O
the	O
images	B:C1704254
;	O
each	O
region	O
corresponded	O
to	O
two	O
of	O
the	O
12	O
biopsy	O
cores	O
.	O

T2	B:C0011923
-	I:C0011923
weighted	I:C0011923
,	O
diffusion	O
-	I:C0598801
weighted	I:C0598801
,	O
and	O
T2	O
-	I:C0011923
weighted	I:C0011923
+	O
diffusion	O
-	I:C0598801
weighted	I:C0598801
scores	O
were	O
computed	O
according	O
to	O
Prostate	O
Imaging	I:C4284879
Reporting	I:C4284879
and	I:C4284879
Data	I:C4284879
System	I:C4284879
.	O

T2	O
-	I:C0011923
weighted	I:C0011923
,	O
diffusion	B:C0598801
-	I:C0598801
weighted	I:C0598801
,	O
and	O
T2	O
-	I:C0011923
weighted	I:C0011923
+	O
diffusion	O
-	I:C0598801
weighted	I:C0598801
scores	O
were	O
computed	O
according	O
to	O
Prostate	O
Imaging	I:C4284879
Reporting	I:C4284879
and	I:C4284879
Data	I:C4284879
System	I:C4284879
.	O

T2	O
-	I:C0011923
weighted	I:C0011923
,	O
diffusion	O
-	I:C0598801
weighted	I:C0598801
,	O
and	O
T2	B:C0011923
-	I:C0011923
weighted	I:C0011923
+	O
diffusion	O
-	I:C0598801
weighted	I:C0598801
scores	O
were	O
computed	O
according	O
to	O
Prostate	O
Imaging	I:C4284879
Reporting	I:C4284879
and	I:C4284879
Data	I:C4284879
System	I:C4284879
.	O

T2	O
-	I:C0011923
weighted	I:C0011923
,	O
diffusion	O
-	I:C0598801
weighted	I:C0598801
,	O
and	O
T2	O
-	I:C0011923
weighted	I:C0011923
+	O
diffusion	B:C0598801
-	I:C0598801
weighted	I:C0598801
scores	O
were	O
computed	O
according	O
to	O
Prostate	O
Imaging	I:C4284879
Reporting	I:C4284879
and	I:C4284879
Data	I:C4284879
System	I:C4284879
.	O

T2	O
-	I:C0011923
weighted	I:C0011923
,	O
diffusion	O
-	I:C0598801
weighted	I:C0598801
,	O
and	O
T2	O
-	I:C0011923
weighted	I:C0011923
+	O
diffusion	O
-	I:C0598801
weighted	I:C0598801
scores	O
were	O
computed	O
according	O
to	O
Prostate	B:C4284879
Imaging	I:C4284879
Reporting	I:C4284879
and	I:C4284879
Data	I:C4284879
System	I:C4284879
.	O

The	O
diagnostic	O
accuracy	O
of	O
the	O
Prostate	B:C4284879
Imaging	I:C4284879
Reporting	I:C4284879
and	I:C4284879
Data	I:C4284879
System	I:C4284879
score	O
was	O
evaluated	O
using	O
histopathology	O
of	O
prostate	O
biopsies	I:C0194804
as	O
the	O
reference	O
standard	O
.	O

The	O
diagnostic	O
accuracy	O
of	O
the	O
Prostate	O
Imaging	I:C4284879
Reporting	I:C4284879
and	I:C4284879
Data	I:C4284879
System	I:C4284879
score	O
was	O
evaluated	O
using	O
histopathology	B:C0677043
of	O
prostate	O
biopsies	I:C0194804
as	O
the	O
reference	O
standard	O
.	O

The	O
diagnostic	O
accuracy	O
of	O
the	O
Prostate	O
Imaging	I:C4284879
Reporting	I:C4284879
and	I:C4284879
Data	I:C4284879
System	I:C4284879
score	O
was	O
evaluated	O
using	O
histopathology	O
of	O
prostate	B:C0194804
biopsies	I:C0194804
as	O
the	O
reference	O
standard	O
.	O

prostate	B:C0376358
cancer	I:C0376358
was	O
histologically	O
diagnosed	O
in	O
169	O
(	O
21.2	O
%	O
)	O
regions	O
.	O

Increased	O
Prostate	B:C4284879
Imaging	I:C4284879
Reporting	I:C4284879
and	I:C4284879
Data	I:C4284879
System	I:C4284879
score	O
correlated	O
positively	O
with	O
increased	O
cancer	O
detection	I:C1516193
rate	O
.	O

Increased	O
Prostate	O
Imaging	I:C4284879
Reporting	I:C4284879
and	I:C4284879
Data	I:C4284879
System	I:C4284879
score	O
correlated	O
positively	O
with	O
increased	O
cancer	B:C1516193
detection	I:C1516193
rate	O
.	O

The	O
cancer	B:C1516193
detection	I:C1516193
rate	O
for	O
scores	O
1	O
to	O
5	O
was	O
2.8	O
%	O
,	O
15.0	O
%	O
,	O
34.6	O
%	O
,	O
52.6	O
%	O
,	O
and	O
88.9	O
%	O
,	O
respectively	O
,	O
using	O
T2	O
-	I:C0011923
weighted	I:C0011923
and	O
12.0	O
%	O
,	O
20.2	O
%	O
,	O
48.0	O
%	O
,	O
85.7	O
%	O
,	O
and	O
93.3	O
%	O
,	O
respectively	O
,	O
using	O
diffusion	O
-	I:C0598801
weighted	I:C0598801
.	O

The	O
cancer	O
detection	I:C1516193
rate	O
for	O
scores	O
1	O
to	O
5	O
was	O
2.8	O
%	O
,	O
15.0	O
%	O
,	O
34.6	O
%	O
,	O
52.6	O
%	O
,	O
and	O
88.9	O
%	O
,	O
respectively	O
,	O
using	O
T2	B:C0011923
-	I:C0011923
weighted	I:C0011923
and	O
12.0	O
%	O
,	O
20.2	O
%	O
,	O
48.0	O
%	O
,	O
85.7	O
%	O
,	O
and	O
93.3	O
%	O
,	O
respectively	O
,	O
using	O
diffusion	O
-	I:C0598801
weighted	I:C0598801
.	O

The	O
cancer	O
detection	I:C1516193
rate	O
for	O
scores	O
1	O
to	O
5	O
was	O
2.8	O
%	O
,	O
15.0	O
%	O
,	O
34.6	O
%	O
,	O
52.6	O
%	O
,	O
and	O
88.9	O
%	O
,	O
respectively	O
,	O
using	O
T2	O
-	I:C0011923
weighted	I:C0011923
and	O
12.0	O
%	O
,	O
20.2	O
%	O
,	O
48.0	O
%	O
,	O
85.7	O
%	O
,	O
and	O
93.3	O
%	O
,	O
respectively	O
,	O
using	O
diffusion	B:C0598801
-	I:C0598801
weighted	I:C0598801
.	O

For	O
T2	B:C0011923
-	I:C0011923
weighted	I:C0011923
+	O
diffusion	O
-	I:C0598801
weighted	I:C0598801
,	O
the	O
cancer	O
detection	I:C1516193
rate	O
was	O
1.5	O
%	O
(	O
score	O
2	O
)	O
,	O
13.5	O
%	O
(	O
scores	O
3	O
-	O
4	O
)	O
,	O
41.3	O
%	O
(	O
scores	O
5	O
-	O
6	O
)	O
,	O
75.9	O
%	O
(	O
scores	O
7	O
-	O
8	O
)	O
,	O
and	O
92.3	O
%	O
(	O
scores	O
9	O
-	O
10	O
)	O
.	O

For	O
T2	O
-	I:C0011923
weighted	I:C0011923
+	O
diffusion	B:C0598801
-	I:C0598801
weighted	I:C0598801
,	O
the	O
cancer	O
detection	I:C1516193
rate	O
was	O
1.5	O
%	O
(	O
score	O
2	O
)	O
,	O
13.5	O
%	O
(	O
scores	O
3	O
-	O
4	O
)	O
,	O
41.3	O
%	O
(	O
scores	O
5	O
-	O
6	O
)	O
,	O
75.9	O
%	O
(	O
scores	O
7	O
-	O
8	O
)	O
,	O
and	O
92.3	O
%	O
(	O
scores	O
9	O
-	O
10	O
)	O
.	O

For	O
T2	O
-	I:C0011923
weighted	I:C0011923
+	O
diffusion	O
-	I:C0598801
weighted	I:C0598801
,	O
the	O
cancer	B:C1516193
detection	I:C1516193
rate	O
was	O
1.5	O
%	O
(	O
score	O
2	O
)	O
,	O
13.5	O
%	O
(	O
scores	O
3	O
-	O
4	O
)	O
,	O
41.3	O
%	O
(	O
scores	O
5	O
-	O
6	O
)	O
,	O
75.9	O
%	O
(	O
scores	O
7	O
-	O
8	O
)	O
,	O
and	O
92.3	O
%	O
(	O
scores	O
9	O
-	O
10	O
)	O
.	O

The	O
area	O
under	O
the	O
curve	O
for	O
cancer	B:C1516193
detection	I:C1516193
was	O
0.700	O
(	O
T2	O
-	I:C0011923
weighted	I:C0011923
)	O
,	O
0.735	O
(	O
diffusion	O
-	I:C0598801
weighted	I:C0598801
)	O
and	O
0.749	O
(	O
T2	O
-	I:C0011923
weighted	I:C0011923
+	O
diffusion	O
-	I:C0598801
weighted	I:C0598801
)	O
.	O

The	O
area	O
under	O
the	O
curve	O
for	O
cancer	O
detection	I:C1516193
was	O
0.700	O
(	O
T2	B:C0011923
-	I:C0011923
weighted	I:C0011923
)	O
,	O
0.735	O
(	O
diffusion	O
-	I:C0598801
weighted	I:C0598801
)	O
and	O
0.749	O
(	O
T2	O
-	I:C0011923
weighted	I:C0011923
+	O
diffusion	O
-	I:C0598801
weighted	I:C0598801
)	O
.	O

The	O
area	O
under	O
the	O
curve	O
for	O
cancer	O
detection	I:C1516193
was	O
0.700	O
(	O
T2	O
-	I:C0011923
weighted	I:C0011923
)	O
,	O
0.735	O
(	O
diffusion	B:C0598801
-	I:C0598801
weighted	I:C0598801
)	O
and	O
0.749	O
(	O
T2	O
-	I:C0011923
weighted	I:C0011923
+	O
diffusion	O
-	I:C0598801
weighted	I:C0598801
)	O
.	O

The	O
area	O
under	O
the	O
curve	O
for	O
cancer	O
detection	I:C1516193
was	O
0.700	O
(	O
T2	O
-	I:C0011923
weighted	I:C0011923
)	O
,	O
0.735	O
(	O
diffusion	O
-	I:C0598801
weighted	I:C0598801
)	O
and	O
0.749	O
(	O
T2	B:C0011923
-	I:C0011923
weighted	I:C0011923
+	O
diffusion	O
-	I:C0598801
weighted	I:C0598801
)	O
.	O

The	O
area	O
under	O
the	O
curve	O
for	O
cancer	O
detection	I:C1516193
was	O
0.700	O
(	O
T2	O
-	I:C0011923
weighted	I:C0011923
)	O
,	O
0.735	O
(	O
diffusion	O
-	I:C0598801
weighted	I:C0598801
)	O
and	O
0.749	O
(	O
T2	O
-	I:C0011923
weighted	I:C0011923
+	O
diffusion	B:C0598801
-	I:C0598801
weighted	I:C0598801
)	O
.	O

The	O
sensitivity	O
and	O
specificity	O
were	O
53.8	O
%	O
and	O
89.2	O
%	O
,	O
respectively	O
,	O
when	O
using	O
scores	O
5	O
-	O
6	O
as	O
the	O
cutoff	O
value	O
for	O
T2	B:C0011923
-	I:C0011923
weighted	I:C0011923
+	O
diffusion	O
-	I:C0598801
weighted	I:C0598801
.	O

The	O
sensitivity	O
and	O
specificity	O
were	O
53.8	O
%	O
and	O
89.2	O
%	O
,	O
respectively	O
,	O
when	O
using	O
scores	O
5	O
-	O
6	O
as	O
the	O
cutoff	O
value	O
for	O
T2	O
-	I:C0011923
weighted	I:C0011923
+	O
diffusion	B:C0598801
-	I:C0598801
weighted	I:C0598801
.	O

The	O
Prostate	B:C4284879
Imaging	I:C4284879
Reporting	I:C4284879
and	I:C4284879
Data	I:C4284879
System	I:C4284879
score	O
correlates	O
with	O
the	O
PCa	O
detection	I:C0281186
rate	O
in	O
patients	O
with	O
prostate	O
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
<	O
20	O
ng	O
/	O
ml	O
.	O

The	O
Prostate	O
Imaging	I:C4284879
Reporting	I:C4284879
and	I:C4284879
Data	I:C4284879
System	I:C4284879
score	O
correlates	O
with	O
the	O
PCa	B:C0281186
detection	I:C0281186
rate	O
in	O
patients	O
with	O
prostate	O
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
<	O
20	O
ng	O
/	O
ml	O
.	O

The	O
Prostate	O
Imaging	I:C4284879
Reporting	I:C4284879
and	I:C4284879
Data	I:C4284879
System	I:C4284879
score	O
correlates	O
with	O
the	O
PCa	O
detection	I:C0281186
rate	O
in	O
patients	O
with	O
prostate	B:C0138741
-	I:C0138741
specific	I:C0138741
antigen	I:C0138741
<	O
20	O
ng	O
/	O
ml	O
.	O

The	O
summed	O
score	O
of	O
T2	B:C0011923
-	I:C0011923
weighted	I:C0011923
+	O
diffusion	O
-	I:C0598801
weighted	I:C0598801
has	O
the	O
highest	O
accuracy	O
in	O
detection	O
of	O
prostate	O
cancer	I:C0376358
.	O

The	O
summed	O
score	O
of	O
T2	O
-	I:C0011923
weighted	I:C0011923
+	O
diffusion	B:C0598801
-	I:C0598801
weighted	I:C0598801
has	O
the	O
highest	O
accuracy	O
in	O
detection	O
of	O
prostate	O
cancer	I:C0376358
.	O

The	O
summed	O
score	O
of	O
T2	O
-	I:C0011923
weighted	I:C0011923
+	O
diffusion	O
-	I:C0598801
weighted	I:C0598801
has	O
the	O
highest	O
accuracy	O
in	O
detection	O
of	O
prostate	B:C0376358
cancer	I:C0376358
.	O

